Evaluation of patient‐reported outcome measures for on‐demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat

BACKGROUND: Hereditary angioedema (HAE) with C1‐inhibitor deficiency (HAE‐C1‐INH) is characterized by recurrent, debilitating episodes of swelling. Sebetralstat, an investigational oral plasma kallikrein inhibitor, demonstrated promising efficacy for on‐demand treatment of HAE‐C1‐INH in a phase 2 tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohn, Danny M., Aygören‐Pürsün, Emel, Bernstein, Jonathan A., Farkas, Henriette, Lumry, William R., Maurer, Marcus, Zanichelli, Andrea, Iverson, Matthew, Hao, James, Smith, Michael D., Yea, Christopher M., Audhya, Paul K., Riedl, Marc A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476273/
https://www.ncbi.nlm.nih.gov/pubmed/37746795
http://dx.doi.org/10.1002/clt2.12288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476273/
https://www.ncbi.nlm.nih.gov/pubmed/37746795
http://dx.doi.org/10.1002/clt2.12288

Ejemplares similares